Browse News
Filter News
Found 808,226 articles
-
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
-
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
-
In a Phase I/II study, Ultragenyx’s antisense oligonucleotide GTX-102 led to significant cognitive, behavioral, sleep and gross motor improvements in patients with the rare genetic disorder Angelman syndrome.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
4/16/2024
Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.
-
Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib
4/16/2024
Volastra Therapeutics today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).
-
SAB Biotherapeutics Provides SAB-142 Trial Update
4/16/2024
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142.
-
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
4/16/2024
Compass Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors.
-
Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer
4/16/2024
Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced that Keith Westby has joined the company as its inaugural Chief Operating Officer.
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
4/16/2024
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
-
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
4/16/2024
RenovoRx, Inc today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.
-
QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis
4/16/2024
QT Imaging Holdings, Inc. is proud to announce positive data regarding the diagnostic performance of QTI’s Breast Acoustic CT TM Scans for mass detection from its second blinded multi-reader multi-case study.
-
Lupus Accelerating Breakthroughs Consortium Announces Expanded Partnership with U.S. FDA at First Anniversary Meeting
4/16/2024
The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium's first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER).
-
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
4/16/2024
Ferring Pharmaceuticals today announced start up of new studies in the United States (U.S.) for three new ADSTILADRIN in BLadder cancEr (ABLE) clinical trials in patients with non-muscle invasive bladder cancer (NMIBC) with plans to expand select clinical trials outside of the U.S. later this year.
-
Ark Clinical Research Announces Advancing Accessibility for Obesity Through Innovative Research Trials on GLP-1 drugs
4/16/2024
Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.
-
A New Era in Precision Medicine: SimBioSys Announces Strategic Collaboration with Magic Leap to Advance TumorSight Platform with AR Integration
4/16/2024
SimBioSys and Magic Leap join forces to integrate AI-powered TumorSight Viz with AR technology, revolutionizing surgical precision and patient outcomes in cancer care.
-
Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
4/16/2024
Endeavor BioMedicines today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor's continued growth and success.
-
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
4/16/2024
Jaguar Health, Inc. today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC.
-
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
4/16/2024
Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
4/16/2024
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.